نتایج جستجو برای: khartooran erg

تعداد نتایج: 7132  

Journal: :Cancer research 2006
Sven Perner Francesca Demichelis Rameen Beroukhim Folke H Schmidt Juan-Miguel Mosquera Sunita Setlur Joelle Tchinda Scott A Tomlins Matthias D Hofer Kenneth G Pienta Rainer Kuefer Robert Vessella Xiao-Wei Sun Matthew Meyerson Charles Lee William R Sellers Arul M Chinnaiyan Mark A Rubin

Prostate cancer is a common and clinically heterogeneous disease with marked variability in progression. The recent identification of gene fusions of the 5'-untranslated region of TMPRSS2 (21q22.3) with the ETS transcription factor family members, either ERG (21q22.2), ETV1 (7p21.2), or ETV4 (17q21), suggests a mechanism for overexpression of the ETS genes in the majority of prostate cancers. I...

2016
Shan Wang Rahul K. Kollipara Caroline G. Humphries Shi-Hong Ma Ryan Hutchinson Rui Li Javed Siddiqui Scott A. Tomlins Ganesh V. Raj Ralf Kittler

Ets related gene (ERG) is a transcription factor that is overexpressed in 40% of prostate tumors due to a gene fusion between ERG and TMPRSS2. Because ERG functions as a driver of prostate carcinogenesis, understanding the mechanisms that influence its turnover may provide new molecular handles to target the protein. Previously, we found that ERG undergoes ubiquitination and then is deubiquitin...

2014
Jung Kim Longtao Wu Jonathan C. Zhao Hong-Jian Jin Jindan Yu

Chromosomal translocations that juxtapose the androgen-sensitive TMPRSS2 gene promoter to the oncogenic ETS-family transcription factor ERG result in excessive ERG overexpression in approximately 50% of prostate cancer (PCa) patients. Although numerous studies have investigated ERG-downstream genes, such studies have not attempted to examine miRNAs, which however are emerging to be important re...

2013
Lukasz A. Kacprzyk Mark Laible Tatjana Andrasiuk Jan C. Brase Stefan T. Börno Maria Fälth Ruprecht Kuner Hans Lehrach Michal R. Schweiger Holger Sültmann

BACKGROUND Overexpression of ERG transcription factor due to genomic ERG-rearrangements defines a separate molecular subtype of prostate tumors. One of the consequences of ERG accumulation is modulation of the cell's gene expression profile. Tudor domain-containing protein 1 gene (TDRD1) was reported to be differentially expressed between TMPRSS2:ERG-negative and TMPRSS2:ERG-positive prostate c...

Journal: :Endocrine-related cancer 2015
Gustavo Ayala Anna Frolov Deyali Chatterjee Dandan He Susan Hilsenbeck Michael Ittmann

Prostate cancer is the second leading cause of cancer-related death of men in the USA. The TMPRSS2/ERG (T/E) fusion gene is present in approximately 50% of prostate cancers and promotes tumor progression in vivo. The presence of the T/E fusion gene is strongly associated with the expression of ERG protein, but emerging evidence indicates a significant interfocal and intrafocal variability in th...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2008
Ying Hu Albert Dobi Taduru Sreenath Christopher Cook Atekelt Y Tadase Lakshmi Ravindranath Jennifer Cullen Bungo Furusato Yongmei Chen Rajesh L Thangapazham Ahmed Mohamed Chen Sun Isabell A Sesterhenn David G McLeod Gyorgy Petrovics Shiv Srivastava

PURPOSE The expression of the ETS-related gene (ERG) is low or undetectable in benign prostate epithelial cells. High prevalence of ERG overexpression in prostate cancer cells due to TMPRSS2-ERG fusions suggest for causal roles of ERG protein in the neoplastic process. TMPRSS2-ERG fusion junctions have been extensively studied in prostate cancer. However, virtually nothing is known about the na...

Journal: :Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2016
Kathryn L Penney Andreas Pettersson Irene M Shui Rebecca E Graff Peter Kraft Rosina T Lis Howard D Sesso Massimo Loda Lorelei A Mucci

BACKGROUND Numerous genetic variants have been confirmed as prostate cancer risk factors. These variants may confer susceptibility to the development of specific molecular alterations during tumor initiation and progression. The TMPRSS2:ERG gene fusion occurs in roughly 50% of prostate cancers. Genetic risk variants may influence the development of this fusion. We sought to determine whether pr...

2011
Orit Leshem Shalom Madar Ira Kogan-Sakin Iris Kamer Ido Goldstein Ran Brosh Yehudit Cohen Jasmine Jacob-Hirsch Marcelo Ehrlich Shmuel Ben-Sasson Naomi Goldfinger Ron Loewenthal Ephraim Gazit Varda Rotter Raanan Berger

Prostate cancer is the most common non-dermatologic malignancy in men in the Western world. Recently, a frequent chromosomal aberration fusing androgen regulated TMPRSS2 promoter and the ERG gene (TMPRSS2/ERG) was discovered in prostate cancer. Several studies demonstrated cooperation between TMPRSS2/ERG and other defective pathways in cancer progression. However, the unveiling of more specific...

Journal: :American journal of clinical pathology 2012
Allison Young Nallasivam Palanisamy Javed Siddiqui David P Wood John T Wei Arul M Chinnaiyan Lakshmi P Kunju Scott A Tomlins

ERG rearrangements (most commonly transmembrane protease, serine 2 [TMPRSS2]:ERG [T2:ERG] gene fusions) have been identified in approximately 50% of prostate cancers . Quantification of T2:ERG in postdigital rectal examination urine, in combination with PCA3, improves the performance of serum prostate-specific antigen for prostate cancer prediction on biopsy. Here we compared urine T2:ERG and P...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید